SCHEMBL25630359

SCHEMBL25630359

O=S(=O)(O)CCCS(=O)(=O)OO

nearest known ligand 0.46

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
APP P05067 1/20 0.46
PTGS1 P23219 1/20 0.38
PDE4A P27815 1/20 0.38
LMNA P02545 1/20 0.38
SLC6A6 P31641 1/20 0.38
CYP2C19 P33261 1/20 0.38
BLM P54132 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25630357 0.89
SCHEMBL499923 0.83 PTGS1 (0.41) APPPTGS1PDE4ALMNASLC6A6
SCHEMBL576422 0.81 APP (0.48) APPPTGS1PDE4ALMNASLC6A6
SCHEMBL28318417 0.80 FAAH (0.36)
Eprodisate SCHEMBL34216 0.80 APP (0.65) APPPTGS1PDE4ALMNASLC6A6
SCHEMBL29104749 0.77 APP (0.44) APPPTGS1PDE4ALMNASLC6A6
SCHEMBL14975445 0.77 APP (0.44) APPPTGS1PDE4ALMNASLC6A6
SCHEMBL2701823 0.77 APP (0.44) APPPTGS1PDE4ALMNASLC6A6
SCHEMBL12878941 0.77 APP (0.44) APPPTGS1PDE4ALMNASLC6A6
Eprodisate SCHEMBL23795561 0.76 APP (0.61) APPPTGS1PDE4ALMNASLC6A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102696142-B Nonaqueous electrolyte solution, electrochemical device using same, and alkynyl compound used in nonaqueous electrolyte solution UBE INDUSTRIES 2015-06-03 CN claimed
US-7342050-B2 Method for preparing a lactic acid ester composition and use thereof as solvent ROQUETTE FRERES (FR) 2008-03-11 US claimed
EP-1614416-A2 Method for treating amyloidosis QUEEN'S UNIVERSITY AT KINGSTON (CA) 2006-01-11 EP claimed
EP-1060750-B1 Propane-1,3-disulfonic acid and its pharmaceutically acceptable salts for treating amyloidosis UNIV KINGSTON (CA) 2005-12-07 EP claimed
EP-1242357-B1 METHOD FOR PREPARING A LACTIC ACID ESTER COMPOSITION AND USE THEREOF AS SOLVENT ROQUETTE FRERES (FR) 2004-07-21 EP claimed
US-20030008927-A1 Method for preparing a lactic acid ester composition and use thereof as solvent ROQUETTE FRERES (FR) 2003-01-09 US claimed
US-20230352250-A1 PHOTOELECTRIC CONVERSION ELEMENT, PHOTOELECTRIC CONVERSION MODULE, ELECTRONIC DEVICE, AND POWER SUPPLY MODULE RICOH COMPANY, LTD. (JP) 2023-11-02 US disclosed
US-20230343965-A1 SECONDARY BATTERY MURATA MANUFACTURING CO (JP) 2023-10-26 US disclosed
US-20230246229-A1 ORGANIC SULFONATE ELECTROLYTE ADDITIVES FOR ZINC BATTERIES Octet Scientific, Inc. 2023-08-03 US disclosed
US-20230246229-A1 ORGANIC SULFONATE ELECTROLYTE ADDITIVES FOR ZINC BATTERIES Octet Scientific, Inc. 2023-08-03 US disclosed
US-20230198021-A1 ELECTROLYTIC SOLUTION FOR SECONDARY BATTERY, AND SECONDARY BATTERY MURATA MANUFACTURING CO., LTD. (JP) 2023-06-22 US disclosed
US-20230165877-A1 ADMINISTRATION AND DOSAGE OF DIAMINOPHENOTHIAZINES WISTA LABORATORIES LTD. (SG) 2023-06-01 US disclosed
US-20210226242-A1 Systems, Devices, and/or Methods for Fuel Cell Utilizing Reactive Nano Silicate HK INVENT CORPORATION (VN) 2021-07-22 US disclosed
WO-2006008661-A2 DIAGNOSTIC METHODS OF MULTIPLE ORGAN AMYLOIDOSIS NEUROCHEM (INTERNATIONAL) LIMITED (CH) 2006-01-26 WO disclosed
EP-1614416-A2 Method for treating amyloidosis QUEEN'S UNIVERSITY AT KINGSTON (CA) 2006-01-11 EP disclosed
EP-1060750-B1 Propane-1,3-disulfonic acid and its pharmaceutically acceptable salts for treating amyloidosis UNIV KINGSTON (CA) 2005-12-07 EP disclosed
US-20030008927-A1 Method for preparing a lactic acid ester composition and use thereof as solvent ROQUETTE FRERES (FR) 2003-01-09 US disclosed
EP-1060750-A2 Method for treating amyloidosis Queen's University at Kingston (CA) 2000-12-20 EP disclosed
EP-0691844-A1 METHOD FOR TREATING AMYLOIDOSIS QUEEN'S UNIVERSITY AT KINGSTON (CA) 1996-01-17 EP disclosed
WO-1994022437-A2 METHOD FOR TREATING AMYLOIDOSIS QUEEN'S UNIVERSITY AT KINGSTON (CA) 1994-10-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230165877-A1 ADMINISTRATION AND DOSAGE OF DIAMINOPHENOTHIAZINES ACHE, BCHE, PNMT APP 111/4885PTGS1 3666/4885PDE4A 759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.